You're signed outSign in or to get full access.
Lion Point Capital, LP
Lion Point Capital is a global investment firm that seeks to invest in equity and debt securities of undervalued public and private companies, employing a value-oriented investment philosophy to activist opportunities across the capital structure.
Investment Strategy
Global special situations with a focus on value-oriented investment and activist opportunities
Latest 13F Filing Activity
Lion Point Capital, LP filed their most recent 13F report on Jun 30, 2025 disclosing 19 equity positions with a total 13F market value of $15M. The fund increased holdings in Milestone Pharmaceuticals in, Fennec Pharmaceuticals Inc., Kiniksa Pharmaceuticals Intl among other positions. Lion Point Capital, LP reduced exposure to Insmed Inc., Bluebird Bio Inc., Ardelyx Inc. among others.
Top Holdings
Equity Positions (19)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
F FENC | FENNEC PHARMACEUTICALS INC | 11.03% | $1.6M | 195,700 | $8.59 | $8.30 | +$432.5K |
A ARDX | ARDELYX INC | 8.93% | $1.3M | 335,400 | $2.55 | $3.92 | -$332.0K |
K KNSA | KINIKSA PHARMACEUTICALS INTL | 8.62% | $1.3M | 45,900 | $18.00 | $27.67 | +$250.6K |
B BBIO | BRIDGEBIO PHARMA INC | 7.62% | $1.1M | 26,000 | $25.20 | $43.18 | +$223.9K |
I INSM | INSMED INC | 7.28% | $1.1M | 10,650 | $21.29 | $100.64 | -$1.3M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more